Rise Therapeutics LLC
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Rheumatoid Arthritis. Patients will take an oral dosage of probiotic (R-2487) and physicians will assess and measure their Rheumatoid Arthritis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-2487) on fecal level will also be measured.
Arthritis, Rheumatoid
R-2487
PHASE1
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 36 participants |
Masking : | NONE |
Primary Purpose : | TREATMENT |
Official Title : | A Single and Repeat Dosing Study of the Safety, Drug Exposure and Clinical Activity of R-2487 in Patients With Rheumatoid Arthritis |
Actual Study Start Date : | 2023-10-19 |
Estimated Primary Completion Date : | 2025-11 |
Estimated Study Completion Date : | 2026-01 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years to 75 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
St.Jude Clinical Research
Doral, Florida, United States, 33172
RECRUITING
AP Medical Research
Miami, Florida, United States, 33165
NOT YET RECRUITING
Dartmouth Hitchcock Medical Center (DHMC)
Lebanon, New Hampshire, United States, 03766
RECRUITING
Altoona Center for Research
Duncansville, Pennsylvania, United States, 16635